No Abstract Available.
Trabeculectomy*

The safety and success rate of trabeculectomy using fornix-based conjunctival flaps were investigated. Patients with chronic angle-closure glaucoma(22 eyes), primary open-angle glaucoma(10 eyes), secondary glaucoma(4 eyes) and ocular hypertension(1 eye) had a trabeculectomy with a fornix-based conjunctival flap. We analyzed the results of these 37 eyes and compared them witih those of trabeculectomy using a lmbus-based codjunctival flap Trabeculectomy was equally successful(intraocular pressure, trabeculectomy using a fornix-based conjunctival flap.
Humans ; Trabeculectomy*

A prospective study was conducted on 56 patients (56 yes) who underwent trabeculectomy to treat glaucoma and had blurred vision due to cataract. Most patients were 70-80 years old (60.7%). Patients with closed-angle glaucoma were 80.4%. Majority of eyes (42 eyes, 74.8%) had bad visual acuity (<1/10). Postoperatively, 23 eyes (41%) achieved visual acuity from 3/10 to 7/10. Between 1 and 6 months postoperative, visual acuity improved significantly and quite stable during follow-up period with 30 eyes (53.5 %) achieved acuity of 5/10 or better. One month after operation, there were 30 eyes (54.2%) with intraocular pressure<18mmHg and 26 eyes (45.8%) with previous inflammation discharged membrane, disengage or cutting the pupil edge, all are mechanic effects which affect to cornea endothelium and iris
Phacoemulsification ; Trabeculectomy

Objective: We described an adjustable traction technique for glaucoma surgeries that provided adequate visualization of the surgical field. Methods: A prototype device was designed to provide good exposure of the surgical site by using a peripheral lamellar trans-corneal suture capable of applying and sustaining tension. Adjustments to the amount of traction required were made through the device. Results: The device was used in 9 cases of glaucoma surgeries: 5 trabeculectomies and 4 glaucoma drainage device implantations. No significant complications were observed. Conclusions The device was easy to use and allowed more flexibility for the surgeon.
Glaucoma ; Trabeculectomy

Glaucoma ; Trabeculectomy

No abstract available.
Humans ; Mitomycin* ; Trabeculectomy*

At The Central Insititute of Opthtalmology from 10/1998 to 11/2003, Trabeculectomy was conducted on 44 eyes of pediatric geaucoma patients with placing a 5 fluouracyt saturated gelaspon (50mg/ml 5 F.U on 2 x 2mm gelaspon flap) under the diseased eye in 5 minutes, then 5- FU was washed away with Ruiger lactat solution. The surgery was efficacious for treating glaucome in young person and children.
Trabeculectomy ; Therapeutics ; Glaucoma ; Adolescent

40 patients (51 eyes, 17 males, 23 females) having cataract combined open or closure angle glaucoma have been operated by Phaco method, implant IOL and trabeculectomy at Ophthalmology Hospital from January to September 2003. The results: Phaco method, implant IOL combined with trabecolectomy have a good effect in regulating IOP. 100% IOP regulated, mean reducing of IOP are 12mmHg. After 6 months periods, no recurrent case of IOP. Post operation, sight improves fast, good and very stable. Sight rate gained 5/10 (66.7%)
Surgery ; Eye ; Trabeculectomy

The purpose of this study is to compare the effects of three different concentrations of mitomycin-C(MMC) as an adjunct therapy to trabeculectomy. We reviewed 26 patients(36 eyes) who underwent trabeculectomy in which MMC was applied intraoperatively. The application time was 5 minute, and concentration of MMC was 0.1mg/ml(n=10), 0.2mg/ml(n=17) and 0.41mg/ml(n=9) respectively. The mean IOP at postoperative 3 months was significantly lower in 0.4mg/ml group (10.4 +/- 5.5mmHg) than in the 0.2mg/ml group(16.1 +/- 4.7mmHg)(p<0.05). There was no statistical difference among the three groups in the success rate regardless of medication, the size and longevity of bleb. The postoperative hypotony(2 eyes) was noted in the 0.4mg/ml group. In conclusions, It is desirable to use the lowest concentration of MMC that will facilitate bleb formation.
Blister ; Longevity ; Mitomycin* ; Trabeculectomy*

Objective: To determine the effect of topically administered bevacizumab on bleb survival and histology after trabeculectomy in rabbit eyes. Methods: This is an experimental interventional comparative animal study. Sixteen rabbit eyes underwent trabeculectomy, 8 of which were enhanced with intraoperative mitomycin-C. Eyes were randomized to receive either topical balanced salt solution (BSS) or topical bevacizumab at a concentration of 12.5 mg/mL. Intraocular pressure, bleb dimensions and vascularity grading were measured. IOP was recorded as a ratio of IOP of the experimental operated eye divided by the IOP of the contralateral control eye (IOPratio) as a function of time. Bleb morphology was recorded as a percentage of the maximum estimated bleb volume (% bleb) as a function of time. Bleb failure occurred if IOPratio ≥0.8, or if % bleb=0. The eyes were then submitted for histopathological analysis after bleb failure has occurred. Results: In plain trabeculectomy, the mean bleb survival in terms of IOP were 6.3 and 9.2 days in the BSS and topical bevacizumab groups respectively (ρ=0.25). In mitomycin-C-enhanced trabeculectomy, the mean bleb survival was 16 and 18.2 days respectively (ρ=0.40). In plain trabeculectomy, mean bleb survival in terms of bleb morphology were 8 and 12.2 days for the BSS and bevacizumab groups respectively (ρ=0.08). In enhanced trabeculectomy, mean bleb survival were 19.5 and 20 days respectively (ρ=0.99). Mean vascularity grading were 2 and 1.9 for the BSS groups, and 1.6 and 1.4 for the bevacizumab groups. Conclusion Topical bevacizumab as adjunctive therapy after trabeculectomy, whether plain or enhanced with mitomycin-C, showed a trend towards prolonged bleb survival, even though the results of this study were not statistically significant.
Bevacizumab ; Trabeculectomy ; Mitomycin